Sulfonilureas y riesgo de fractura en pacientes con diabetes mellitus tipo 2: una revisión sistemática y un metaanálisis

IF 1.7 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Revista clinica espanola Pub Date : 2026-10-01 Epub Date: 2026-07-06 DOI:10.1016/j.rce.2026.502596

L. Xu, R. Yuan, H. Yue, M. Wang, W. Cai

{"title":"Sulfonilureas y riesgo de fractura en pacientes con diabetes mellitus tipo 2: una revisión sistemática y un metaanálisis","authors":"L. Xu, R. Yuan, H. Yue, M. Wang, W. Cai","doi":"10.1016/j.rce.2026.502596","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the association between sulfonylureas and fracture risk in patients with type 2 diabetes mellitus (T2DM).</div></div><div><h3>Methods</h3><div>PubMed, Web of Science, the Cochrane Library and Embase were systematically searched for observational studies evaluating sulfonylurea-associated fracture risk in patients with T2DM. Pooled relative risk (RR) and its 95% confidence interval (CI) were calculated.</div></div><div><h3>Results</h3><div>Twelve observational studies involving 5,854,139 patients were included. Sulfonylurea use was significantly associated with increased risks of overall fractures (RR=1.28; 95% CI: 1.11–1.47) and osteoporotic fractures (RR=1.38; 95% CI: 1.05–1.80). Site-specific analyses revealed a 23% increase in hip fracture risk (RR=1.23; 95% CI: 1.03–1.46) and a 47% increase in vertebral fracture risk (RR=1.47; 95% CI: 1.24–1.74). Fracture risk profiles varied across sulfonylurea subtypes.</div></div><div><h3>Conclusion</h3><div>Sulfonylureas are associated with a significant increase in the overall risk of fractures and the risk of osteoporotic fractures in patients with T2DM, and this risk is particularly prominent in hip and vertebral fractures.</div></div>","PeriodicalId":21223,"journal":{"name":"Revista clinica espanola","volume":"226 8","pages":"Article 502596"},"PeriodicalIF":1.7000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista clinica espanola","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0014256526012051","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

To evaluate the association between sulfonylureas and fracture risk in patients with type 2 diabetes mellitus (T2DM).

Methods

PubMed, Web of Science, the Cochrane Library and Embase were systematically searched for observational studies evaluating sulfonylurea-associated fracture risk in patients with T2DM. Pooled relative risk (RR) and its 95% confidence interval (CI) were calculated.

Results

Twelve observational studies involving 5,854,139 patients were included. Sulfonylurea use was significantly associated with increased risks of overall fractures (RR = 1.28; 95% CI: 1.11–1.47) and osteoporotic fractures (RR = 1.38; 95% CI: 1.05–1.80). Site-specific analyses revealed a 23% increase in hip fracture risk (RR = 1.23; 95% CI: 1.03–1.46) and a 47% increase in vertebral fracture risk (RR = 1.47; 95% CI: 1.24–1.74). Fracture risk profiles varied across sulfonylurea subtypes.

Conclusion

Sulfonylureas are associated with a significant increase in the overall risk of fractures and the risk of osteoporotic fractures in patients with T2DM, and this risk is particularly prominent in hip and vertebral fractures.

查看原文本刊更多论文

2型糖尿病患者的磺胺脲和骨折风险：系统综述和荟萃分析

目的探讨磺脲类药物与2型糖尿病（T2DM）患者骨折风险的关系。方法系统检索spubmed、Web of Science、Cochrane Library和Embase，以评估磺脲类药物在T2DM患者中的骨折风险。计算合并相对危险度（RR）及其95%置信区间（CI）。结果纳入12项观察性研究，涉及5,854,139例患者。磺脲类药物的使用显著增加了整体骨折（RR = 1.28; 95% CI: 1.11-1.47）和骨质疏松性骨折（RR = 1.38; 95% CI: 1.05-1.80）的风险。部位特异性分析显示，髋部骨折风险增加23% (RR = 1.23; 95% CI: 1.03-1.46)，椎体骨折风险增加47% （RR = 1.47; 95% CI: 1.24-1.74）。不同磺酰脲亚型的骨折风险谱不同。结论磺脲类药物与T2DM患者总体骨折风险和骨质疏松性骨折风险显著升高相关，且在髋部和椎体骨折中尤为突出。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista clinica espanola 医学-医学：内科

CiteScore

4.40

自引率

6.90%

发文量

审稿时长

28 days

期刊介绍： Revista Clínica Española published its first issue in 1940 and is the body of expression of the Spanish Society of Internal Medicine (SEMI). The journal fully endorses the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice. Revista Clínica Española is subject to a thorough double blind review of the received articles written in Spanish or English. Nine issues are published each year, including mostly originals, reviews and consensus documents.